Evidence map›Paper›PMID 33586513›Full record

ArticleJournal of managed care & specialty pharmacy2021

Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma.

Scott J Spencer, Gregory F Guzauskas, Federico FeLizzi, Aino Launonen, Keith Dawson, David L Veenstra, Anthony Masaquel

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of managed care & specialty pharmacy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Scott J SpencerUniversity of Washington Institute for Public Health Genetics, Seattle.
Gregory F GuzauskasUniversity of Washington Department of Pharmacy, Seattle.
Federico FeLizziF. Hoffmann-La Roche, Basel, Switzerland.
Aino LaunonenF. Hoffmann-La Roche, Basel, Switzerland.
Keith DawsonGenentech, South San Francisco, CA.
David L VeenstraUniversity of Washington Department of Pharmacy, Seattle.
Anthony MasaquelGenentech, South San Francisco, CA.
Roche (Switzerland) · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalBiosimilar PharmaceuticalsCost-Benefit AnalysisDrug CostsHumansLymphoma, FollicularMarkov ChainsQuality-Adjusted Life YearsRituximabUnited StatesAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalBiosimilar PharmaceuticalsobinutuzumabRituximab

Identifiers

PMID33586513
PMCPMC10394221
OpenAlexW3130577028

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.